Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report) Director Johnny D. Powers bought 100,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was acquired at an average price of $0.17 per share, for a total transaction of $17,000.00. Following the acquisition, the director now directly owns 1,850,000 shares in the company, valued at $314,500. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Zomedica Price Performance
Shares of ZOM traded up $0.01 on Monday, reaching $0.18. The company’s stock had a trading volume of 3,641,033 shares, compared to its average volume of 5,255,079. Zomedica Corp. has a twelve month low of $0.15 and a twelve month high of $0.34. The firm has a market capitalization of $171.79 million, a PE ratio of -5.57 and a beta of 0.98.
Institutional Investors Weigh In On Zomedica
Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC grew its position in Zomedica by 1,047.0% in the 1st quarter. Virtu Financial LLC now owns 198,888 shares of the company’s stock worth $42,000 after purchasing an additional 181,548 shares in the last quarter. UBS Group AG grew its position in Zomedica by 207.6% in the 1st quarter. UBS Group AG now owns 200,000 shares of the company’s stock worth $67,000 after purchasing an additional 134,984 shares in the last quarter. Commonwealth Equity Services LLC grew its position in Zomedica by 27.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 275,175 shares of the company’s stock worth $58,000 after purchasing an additional 60,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Zomedica by 76.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 332,000 shares of the company’s stock worth $54,000 after purchasing an additional 144,000 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Zomedica by 62.9% in the 4th quarter. Jane Street Group LLC now owns 269,728 shares of the company’s stock worth $44,000 after purchasing an additional 104,143 shares in the last quarter. 9.89% of the stock is owned by institutional investors.
Zomedica Company Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health.
- Five stocks we like better than Zomedica
- What is the Euro STOXX 50 Index?
- The most upgraded stocks in November have two things in common
- How to Choose Top Rated Stocks
- Monday.com rocked earnings like it’s the weekend
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Plan to own one retailer? Make it this one
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.